IBM released earnings that were better than expected. Although the results were mixed, investors should be taking a closer look at the stock.
A significant correction is an inevitability at some point, if history is any guide. Here are three stocks to buy if the opportunity arises.
Macroeconomic factors have clouded Cisco's recent performance. With those clouds now parting, the stock deserves a second look.
The energy sector seems overdue for a rebound. Chevron may be the best way to play it.
Berkshire has lagged the market over the recent past. It's time for the shares to play catch up.
On many dimensions, Accenture qualifies as a great company. But is it a great investment?
This big pharma stock provides value in an increasingly expensive market.
The Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.
IBM is lagging behind its technology peers. But its acquisition of Red Hat earlier this year may be a game changer.
With a new CEO on board, Wells Fargo can start to put its problems behind it.
Persistent bad news has driven the tobacco company to its lowest valuation in 10 years. It’s time to have a second look.
It’s been a rough ride for Gilead Sciences. But the biotech may soon be sailing through smoother seas.